Short communication: Expression of transporters and metabolizing enzymes in the female lower genital tract: Implications for microbicide research

AIDS Research and Human Retroviruses

Volumn 29, Issue 11, 2013, Pages 1496-1503

  Zhou, Tian ^a,b   Hu, Minlu ^a,b   Cost, Marilyn ^b   Poloyac, Samuel ^a   Rohan, Lisa ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CYTOCHROME P450; DARUNAVIR; DIDANOSINE; DRUG METABOLIZING ENZYME; EFAVIRENZ; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GLUCURONOSYLTRANSFERASE 1A1; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; MESSENGER RNA; MICROBICIDE; MULTIDRUG RESISTANCE PROTEIN; NELFINAVIR; NEVIRAPINE; OCTAMER TRANSCRIPTION FACTOR 2; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

ANIMAL EXPERIMENT; ARTICLE; DRUG DISTRIBUTION; DRUG METABOLISM; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN TISSUE; LIVER; MOUSE; NONHUMAN; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE ECTOCERVIX; VAGINA;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFECTIVE AGENTS; ENZYMES; FEMALE; GENE EXPRESSION PROFILING; GENITALIA, FEMALE; HIV INFECTIONS; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84886712328     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0032     Document Type: Article

References (36)

1. Haase AT: Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464(7286): 217-223.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329(5996): 1168-1174.
3. Adams JL and Kashuba AD: Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol 2012; 26(4): 451-462.
4. Kis O, Robillard K, Chan GN, and Bendayan R: The complexities of antiretroviral drug-drug interactions: Role of ABC and SLC transporters. Trends Pharmacol Sci 2010; 31(1): 22-35.
5. Hendrix CMA, Guddera V, et al.: MTN-001: A Phase 2 Cross-over Study of Daily Oral and Vaginal TFV in Healthy, Sexually Active Women Results in Significantly Different Product Acceptability and Vaginal Tissue Drug Concentrations. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections, 2011.
6. Schwartz JL, Rountree W, Kashuba AD, et al.: A multicompartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 2011; 6(10): e25974.
7. Karim SS, Kashuba AD, Werner L, and Karim QA: Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: Implications for HIV prevention in women. Lancet 2011; 378(9787): 279-281.
8. Ho RH and Kim RB: Transporters and drug therapy: Implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78(3): 260-277.
9. Giacomini KM, Huang SM, Tweedie DJ, et al.: Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9(3): 215-236.
10. Minuesa G, Huber-Ruano I, Pastor-Anglada M, Koepsell H, Clotet B, and Martinez-Picado J: Drug uptake transporters in antiretroviral therapy. Pharmacol Ther 2011; 132(3): 268-279.
11. Veazey RS, Shattock RJ, Klasse PJ, and Moore JP: Animal models for microbicide studies. Curr HIV Res 2012; 10(1): 79-87.
12. Catalone BJ, Kish-Catalone TM, Budgeon LR, et al.: Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother 2004; 48(5): 1837-1847.
13. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, and Karlsson J: Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007; 35(8): 1333-1340.
14. Abel S, Back DJ, and Vourvahis M: Maraviroc: Pharmacokinetics and drug interactions. Antivir Ther 2009; 14(5): 607-618.
15. Kohler JJ, Hosseini SH, Green E, et al.: Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 2011; 91(6): 852-858.
16. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, and Sugiyama Y: Functional involvement of multidrug resistance- associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 2007; 71(2): 619-627.
17. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, et al.: Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis 2011; 204(1): 145-153.
18. Minuesa G, Volk C, Molina-Arcas M, et al.: Transport of lamivudine [(-)-beta-L-2', 3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 2009; 329(1): 252-261.
19. Jung N, Lehmann C, Rubbert A, et al.: Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 2008; 36(8): 1616-1623.
20. Govindarajan R, Leung GP, Zhou M, Tse CM, Wang J, and Unadkat JD: Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol 2009; 296(4): G910-922.
21. Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, and Young JD: Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol 2001; 18(2): 161-167.
22. Bieche I, Narjoz C, Asselah T, et al.: Reverse transcriptase- PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 2007; 17(9): 731-742.
23. Bleasby K, Castle JC, Roberts CJ, et al.: Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition. Xenobiotica 2006; 36(10-11): 963-988.
24. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, and Yokoi T: Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 2008; 36(8): 1461-1464.
25. Schneider J, Efferth T, Mattern J, Rodriguez-Escudero FJ, and Volm M: Immunohistochemical detection of the multi-drugresistance marker P-glycoprotein in uterine cervical carcinomas and normal cervical tissue. Am J Obstet Gynecol 1992; 166(3): 825-829.
26. Maliepaard M, Scheffer GL, Faneyte IF, et al.: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61(8): 3458-3464.
27. Farin FM, Bigler LG, Oda D, McDougall JK, and Omiecinski CJ: Expression of cytochrome P450 and microsomal epoxide hydrolase in cervical and oral epithelial cells immortalized by human papillomavirus type 16 E6/E7 genes. Carcinogenesis 1995; 16(6): 1391-1401.
28. Yokose T, Doy M, Taniguchi T, et al.: Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues. Virchows Arch 1999; 434(5): 401-411.
29. Patel KR, Astley S, Adams DJ, Lacey CJ, Ali SW, and Wells M: Expression of cytochrome P450 enzymes in the cervix. An immunohistochemical study. Int J Gynecol Cancer 1993; 3(3): 159-163.
30. Feldman DN, Feldman JG, Greenblatt R, et al.: CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women. AIDS Educ Prev 2009; 21(3 Suppl): 81-93.
31. Rendic S and Guengerich FP: Update information on drug metabolism systems-2009, part II: Summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 2010; 11(1): 4-84.
32. Bjornerem A, Straume B, Midtby M, et al.: Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic diseases in a general population: The Tromso Study. J Clin Endocrinol Metab 2004; 89(12): 6039-6047.
33. D'Cruz OJ, Waurzyniakt B, and Uckun FM: A 13-week subchronic intravaginal toxicity study of pokeweed antiviral protein in mice. Phytomedicine 2004; 11(4): 342-351.
34. D'Cruz OJ and Uckun FM: Lack of adverse effects on fertility of female CD-1 mice exposed to repetitive intravaginal gel-microemulsion formulation of a dual-function anti-HIV agent: Aryl phosphate derivative of bromo- methoxyzidovudine (compound WHI-07). J Appl Toxicol 2001; 21(4): 317-322.
35. Segarra TJ, Fakioglu E, Cheshenko N, et al.: Bridging the gap between preclinical and clinical microbicide trials: Blind evaluation of candidate gels in murine models of efficacy and safety. PLoS One 2011; 6(11): e27675.
36. Catalone BJ, Kish-Catalone TM, Neely EB, et al.: Comparative safety evaluation of the candidate vaginal microbicide C31G. Antimicrob Agents Chemother 2005; 49(4): 1509-1520.